$2,995.00
The market environment in Spain is extremely challenging, with cost-containment measures introduced in 2010–12 contributing to an overall reduction in pharmaceutical spending.
Continued stagnation as generics and price cuts erode market value
The market environment in Spain is extremely challenging, with cost-containment measures introduced in 2010–12 contributing to an overall reduction in pharmaceutical spending. The changes are multi-pronged and appear to single out the branded sector, amid misplaced perceptions that Spain’s drugs bill is excessive.
Key growth drivers for the pharmaceutical industry in Spain include growing use of high value innovative treatments for chronic diseases driven by an aging population, but it remains to be seen to what extent the innovative industry stands to benefit materially from this trend. Generic erosion is now a significant market risk. The Spanish government has, however, restored some confidence by settling most of its outstanding obligations to the pharmaceutical industry and committing significant resource to the domestic life sciences research sector.
Table of Contents
5 EXECUTIVE SUMMARY
5 Catalyst
5 Key findings
7 HEALTHCARE EXPENDITURE
7 Spain has a lower healthcare spend per capita compared to other developed markets
10 Settlement of SNS debts to pharmaceutical companies is a positive point
11 INSURANCE AND HEALTHCARE SYSTEM
11 Key healthcare regulatory bodies
12 Health insurance is provided primarily through the SNS and supported by supplementary
private healthcare
17 Primary care versus hospital care in Spain: primary care is delivered in primary healthcare
centers
19 Healthcare reforms in Spain have focused on reducing costs
24 REGULATORY ISSUES
24 Drug approval and regulatory processes in Spain
28 Intellectual property issues in Spain
29 Data exclusivity issues in Spain – the 8+2+1 rule
30 Clinical trials regulation in Spain
31 Drug counterfeiting in Spain
31 Parallel trade
34 BIBLIOGRAPHY
34 Publications and online articles
42 APPENDIX
42 Contributors
42 Exchange rates used in this report
List of figures
7 Figure 1: Spain – healthcare spending comparison to other key markets, 2010
12 Figure 2: Spain – health insurance system
13 Figure 3: Spain – healthcare system by source of funding
15 Figure 4: Spain – different levels of control of healthcare system functions
24 Figure 5: Spain – routes to obtaining marketing authorization
30 Figure 6: EU – the 8+2+1 market exclusivity rule
List of Tables
9 Table 1: Spain – healthcare expenditure indicators, 2006–09
17 Table 2: Spain – primary versus specialist care
18 Table 3: Spain – hospital bed and healthcare worker density, 2004–10
19 Table 4: Spain – major healthcare reforms, 1984–2012
22 Table 5: Spain – selected regional cost containment initiatives in 2010–12
42 Table 6: Currency exchange rates, 2011
Figure 1: Spain – healthcare spending comparison to other key markets, 2010
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!